UA138854U - METHOD FOR PREDICTING THE DEVELOPMENT OF OSTEOARTHRITIS - Google Patents

Abstract

The method of predicting the development of osteoarthritis includes a clinical examination, radiography. Additionally, in the patient's serum determine the polymorphism of genes methylenetetrahydrofolate reductase (MTHFR C677T), nitric oxide synthase (eNOS T786C), the content of endothelin, folic acid, oxyproline, C-reactive protein (CP-6), interl. With a homozygous carrier of 677-TT, 786-CC and endothelin levels> 10 ng / ml, folic acid <6 ng / ml, oxyproline> 15 μmol / l, PSA> 6 mg / l, IL-6> 10 ng / l predict development of osteoarthritis.

Description

The proposed useful model for predicting the development of osteoarthritis belongs to medicine, in particular to orthopedics and rheumatology. The method is intended and can be used in diagnosing the development of osteoarthritis in the early stages.

Methods of predicting the development of osteoarthritis are known. These include x-rays, studies of biopsies of the synovial membrane, synovial fluid, and cartilage biopsies (A.N.

Okorokov Diagnosis of diseases of internal organs. - M., 2001. - Vol. 2. - P. 186-196). The disadvantage of these methods is the lack of the possibility of predicting the dynamics of the process in the early subclinical stages, preventing its development and possible complications due to the internal characteristics of the body.

The basis of a useful model is the task of developing a method that would allow predicting the development of osteoarthritis in the early stages.

The task is solved by the fact that, in addition to conducting a clinical examination and radiography, the polymorphism of the genes methylenetetrahydrofolate reductase (MTNEV C677T), nitric oxide synthase (6МО5 17860), the content of endothelin, folic acid, oxyproline, C-reactive protein (CRP) is determined in the patient's blood serum , interleukin 6 (IL-6). With homozygous carriers of 677-TT, 786-SS, levels of endothelin "10 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, SRP 26 mg/l, IL-6 "10 ng/l predict the development of osteoarthritis .

Application of the method.

During hospitalization, the patient is examined, x-rays are taken, MINEK C677T, eMmOo5 T786C gene polymorphisms are determined, the content of endothelin, folic acid, oxyproline, SRP, IL-6 is determined by the immunoenzymatic method. With homozygous carrier 677-TT, 786-SS, levels of endothelin "10 ng/ml, folic acid "6 ng/ml, oxyproline 215 μmol/l, SRP "6 mg/l, IL-6 "10 ng/l predict the development osteoarthritis

A specific example of using the method.

Patient D., 60 years old, was hospitalized in the clinic due to pain syndrome in the left knee joint. Examined, X-ray taken. No signs of osteoarthritis were found. Polymorphisms of MTNEV C677T and emo5 17860 genes were determined in blood serum. The content of endothelin, folic acid, oxyproline, SRP, IL-6 was determined by immunoenzymatic method. A homozygous carrier of 677-TT and 786-SS was established, endothelin levels - 22 ng/ml, folic acid - 3.5 ng/ml,

From oxyproline - 38 μmol/l, SRP - 15 mg/l, IL-6 - 24 ng/l. The development of osteoarthritis was diagnosed.

After 12 months, X-rays revealed signs of osteoarthritis.

Thus, the proposed method is informative and allows diagnosing the development of osteoarthritis at an early stage.

Claims (1)

USEFUL MODEL FORMULA A method of predicting the development of osteoarthritis, which includes a clinical examination and radiography, which is distinguished by the fact that polymorphisms of the methylenetetrahydrofolate reductase (MINEV Sb677T) and nitric oxide synthase genes are additionally determined in the patient's blood serum (emo5 1786C), the content of endothelin, folic acid, oxyprolin, C-reactive protein (CRP), interleukin 6 (IL-6) and with homozygous carriers of 677-TT, 786-SS and endothelin levels of 210 ng/ml, folic acid " 6 ng/ml, oxyproline »15 μmol/l, SRP »6 mg/l, IL-6 »10 ng/l predict the development of osteoarthritis.